10x Genomics, Inc. (TXG) stock
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30111% above fair value
$56.30+1.31 (+2.38%)
Close on Nov 17, 2026Market cap $7.34BP/E –Yield –
10x Genomics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
10x Genomics's operating cash flow for the twelve months ending Sep 30, 2026 was $99.70M, up 12.6% year over year. For fiscal 2025 it was $136.05M, up 1941.6% from the year before. The highest annual figure on record is $136.05M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $136.05M | +1941.6% |
| FY2024 | Dec 31, 2024 | $6.66M | – |
| FY2023 | Dec 31, 2023 | -$15.20M | – |
| FY2022 | Dec 31, 2022 | -$33.61M | – |
| FY2021 | Dec 31, 2021 | -$21.37M | – |
| FY2020 | Dec 31, 2020 | -$217.90M | -729.3% |
| FY2019 | Dec 31, 2019 | $34.63M | – |
| FY2018 | Dec 31, 2018 | -$76.41M | – |
| FY2017 | Dec 31, 2017 | -$10.70M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $15.83M | -63.4% |
| Q2 FY2026 | Jun 30, 2026 | $16.97M | -4.1% |
| Q1 FY2026 | Mar 31, 2026 | $26.12M | -24.0% |
| Q4 FY2025 | Dec 31, 2025 | $40.78M | – |
| Q3 FY2025 | Sep 30, 2025 | $43.21M | +99.7% |
| Q2 FY2025 | Jun 30, 2025 | $17.71M | +136.2% |
| Q1 FY2025 | Mar 31, 2025 | $34.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.75M | -126.2% |
| Q3 FY2024 | Sep 30, 2024 | $21.64M | – |
| Q2 FY2024 | Jun 30, 2024 | $7.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.73M | – |
| Q4 FY2023 | Dec 31, 2023 | $25.76M | +87.7% |
| Q3 FY2023 | Sep 30, 2023 | -$25.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.53M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.13M | – |
| Q4 FY2022 | Dec 31, 2022 | $13.72M | +136.4% |
| Q3 FY2022 | Sep 30, 2022 | -$9.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.96M | -643.7% |
| Q1 FY2022 | Mar 31, 2022 | -$20.80M | – |
| Q4 FY2021 | Dec 31, 2021 | $5.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.22M | – |
| Q2 FY2021 | Jun 30, 2021 | $3.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.08M | – |
| Q4 FY2020 | Dec 31, 2020 | -$130.18M | -2042.9% |
| Q3 FY2020 | Sep 30, 2020 | -$55.63M | -483.0% |
| Q2 FY2020 | Jun 30, 2020 | -$29.52M | -822.9% |
| Q1 FY2020 | Mar 31, 2020 | -$2.58M | -127.6% |
| Q4 FY2019 | Dec 31, 2019 | $6.70M | – |
| Q3 FY2019 | Sep 30, 2019 | $14.53M | – |
| Q2 FY2019 | Jun 30, 2019 | $4.08M | – |
| Q1 FY2019 | Mar 31, 2019 | $9.32M | – |
| Q4 FY2018 | Dec 31, 2018 | -$51.00M | – |
See a number that looks wrong?